Selective Janus Kinase Inhibition Preserves Interferon-Λ-mediated Antiviral Responses

Inflammatory diseases are frequently treated with Janus kinase (JAK) inhibitors to diminish cytokine signaling. These treatments can lead to inadvertent immune suppression and may increase the risk of viral infection. Tyrosine kinase 2 (TYK2) is a JAK family member required for efficient type I inte...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Sci Immunol
Päätekijät: Schnepf, Daniel, Crotta, Stefania, Thamamongood, Thiprampai, Stanifer, Megan, Polcik, Laura, Ohnemus, Annette, Vier, Juliane, Jakob, Celia, Llorian, Miriam, Gad, Hans Henrik, Hartmann, Rune, Strobl, Birgit, Kirschnek, Susanne, Boulant, Steeve, Schwemmle, Martin, Wack, Andreas, Staeheli, Peter
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7610871/
https://ncbi.nlm.nih.gov/pubmed/33990378
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciimmunol.abd5318
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia